Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers
Authors:
Open Access
- 1 August 2001
- journal article
- research article
- Published by BMJ in Molecular Pathology
- Vol. 54 (4) , 259-263
Abstract
Background/Aims—It was recently reported that significantly fewer breast tumours of BRCA1 mutation carriers overexpressed cyclin D1 and HER2 protein than tumours of age matched breast cancer cases unselected for family history. This study aimed to examine the genetic basis of this reduction by determining the frequency of tumours within this cohort showing DNA amplification of these genes. Methods—Paraffin wax embedded sections of breast tumours from BRCA1 mutation carriers and age, grade, histological type, and tumour size matched non-familial controls that had previously been stained for cyclin D1 and HER2 protein overexpression were analysed for CCND1 and HER2 gene amplification using fluorescence in situ hybridisation. Results—CCND1 amplification was detected in none of the 30 tumours of the BRCA1 mutation carriers and in 19 of 74 tumours of the matched controls. Of those samples previously determined to overexpress the HER2 protein, HER2 amplification was detected in one of three tumours from BRCA1 mutation carriers and in 13 of 17 tumours of the age matched non-familial cases. Conclusion—None of the tumours of BRCA1 mutation carriers showed CCND1 amplification and only one tumour showed HER2 amplification. In contrast, a large proportion of cyclin D1 and HER2 overexpression in tumours of non-familial breast cancer cases could be accounted for by amplification of these genes. These data suggest that breast tumorigenesis in BRCA1 mutation carriers occurs by a molecular mechanism distinct from that of age matched non-familial cases.Keywords
This publication has 37 references indexed in Scilit:
- Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the MessageJournal of Clinical Oncology, 2001
- Frequency ofBRCA1 andBRCA2 mutations in a clinic-based series of breast and ovarian cancer familiesHuman Mutation, 2000
- HER-2/neu Gene Amplification Compared With HER-2/neu Protein Overexpression and Interobserver Reproducibility in Invasive Breast CarcinomaAmerican Journal of Clinical Pathology, 2000
- Concomitant Oncoprotein Detection with Fluorescence in Situ Hybridization (CODFISH)The Journal of Molecular Diagnostics, 2000
- β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progressionProceedings of the National Academy of Sciences, 2000
- Gene diagnostics provide new insights into breast cancer prognosis and therapyGene, 1995
- Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12–21British Journal of Surgery, 1994
- c-erbB-2 DNA Amplification and mRNA Expression in Human Primary Breast Tumors and Its Relationship to Other Prognostic FactorsCancer Biotherapy, 1993
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987